Related Experiment Video

Updated: Jun 26, 2026

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

Aspirin and Diabetes Mellitus: revisiting an old player

Camila Manrique1, Guido Lastra, John Palmer

  • 1University of Missouri Columbia, Department of Internal Medicine, Endocrinology and Diabetes Department, Harry S Truman VA Hospital, Columbia, MO, 1, Hospital Drive, Columbia, MO 65211, USA.

Therapeutic Advances in Cardiovascular Disease
|January 7, 2009
PubMed

Insights

Type 2 diabetes mellitus increases cardiovascular disease risk. Research explores how aspirin may help manage diabetes and cardiovascular disease by targeting inflammation and platelet function.

Area of Science:

  • Cardiovascular Medicine
  • Endocrinology
  • Pharmacology

Background:

  • Type 2 Diabetes Mellitus (T2DM) is linked to increased cardiovascular disease (CVD) risk.
  • Platelet dysfunction, chronic inflammation, and thrombogenesis are implicated in insulin resistance, T2DM, and CVD.
  • Aspirin, a salicylate, has known cardiovascular benefits and is being investigated for its role in diabetes.

Purpose of the Study:

  • To explore the mechanisms linking T2DM, inflammation, and CVD.
  • To understand the potential therapeutic role of aspirin in managing T2DM and associated CVD.
  • To investigate the influence of salicylates on insulin resistance, glucose homeostasis, and inflammatory pathways.

Main Methods:

  • Review of current research on T2DM pathophysiology and CVD.
  • Analysis of studies investigating salicylate effects on metabolic and inflammatory markers.
  • Examination of the role of the NF-kappaB pathway in T2DM and inflammation.

Main Results:

  • Emerging evidence highlights the role of platelet dysfunction and inflammation in T2DM and CVD.
  • Salicylates, including aspirin, show potential in modulating insulin resistance, glucose homeostasis, and inflammation.
  • Activation of the NF-kappaB pathway is a key area of research in this context.

Conclusions:

  • Understanding the interplay between T2DM, inflammation, and platelet function is crucial for CVD prevention.
  • Aspirin and other salicylates represent a promising therapeutic avenue for managing both diabetes mellitus and atherosclerotic cardiovascular disease.
  • Further research into salicylate mechanisms, particularly NF-kappaB inhibition, is warranted for improved patient outcomes.

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...